SGLT2 Inhibitor Selection for Heart Failure with CKD Stage 3–4
Both empagliflozin (Jardiance) and dapagliflozin are equally effective and interchangeable for chronic heart failure in patients with CKD stage 3–4; choose either agent at 10 mg once daily based on availability, cost, and formulary considerations. 1, 2, 3
Guideline-Based Recommendations
Class I Evidence for Both Agents
The 2021 Canadian Heart Failure guidelines provide strong (Class 1A) recommendations for SGLT2 inhibitors in heart failure with reduced ejection fraction, explicitly including both dapagliflozin and empagliflozin as foundational therapy regardless of diabetes status. 1
KDIGO 2022 and the ADA/KDIGO 2022 consensus statement issue a Class 1A (strong) recommendation for SGLT2 inhibitors in adults with CKD when eGFR ≥20 mL/min/1.73 m², which encompasses all of CKD stage 3 (eGFR 30–59) and stage 4 (eGFR 15–29). 2, 3
Both agents reduce cardiovascular death, heart failure hospitalization, and slow eGFR decline with equivalent efficacy across the spectrum of kidney function down to eGFR 20 mL/min/1.73 m². 1, 2, 3
Renal Function Thresholds
Empagliflozin was studied in EMPEROR-Reduced with enrollment criteria allowing eGFR as low as 20 mL/min/1.73 m², and subgroup analyses confirmed consistent cardiovascular and renal benefits at eGFR 20–30 mL/min/1.73 m². 1, 4, 5
Dapagliflozin in DAPA-HF enrolled patients with eGFR ≥25 mL/min/1.73 m², and subsequent DAPA-CKD data support initiation at eGFR ≥25 mL/min/1.73 m² with continuation even if eGFR falls below 25. 1, 6, 7
FDA labeling for dapagliflozin specifies 10 mg once daily for heart failure and CKD indications when eGFR ≥25 mL/min/1.73 m², while empagliflozin labeling supports use at eGFR ≥20 mL/min/1.73 m² based on EMPEROR trial data. 7, 8
Comparative Efficacy Evidence
No Clinically Meaningful Difference
A 2025 prospective crossover study (n=25) found no significant difference in NT-proBNP levels or clinical outcomes between empagliflozin 10 mg and dapagliflozin 10 mg in stable chronic heart failure patients, supporting their interchangeable use. 9
A 2025 multicenter cohort study (n=4,930 propensity-matched patients) demonstrated no significant difference in the composite of cardiovascular death or heart failure hospitalization between dapagliflozin and empagliflozin (9.8% vs 9.3%; adjusted HR 0.99,95% CI 0.83–1.19), with consistent results across all ejection fraction categories. 10
Both agents reduced the primary composite outcome of cardiovascular death or heart failure hospitalization with nearly identical hazard ratios in their respective landmark trials: DAPA-HF showed HR 0.74 (95% CI 0.65–0.85) and EMPEROR-Reduced showed HR 0.75 (95% CI 0.65–0.86). 1
Kidney-Specific Outcomes
Empagliflozin slowed eGFR decline by 0.55 vs 2.28 mL/min/1.73 m²/year in EMPEROR-Reduced and reduced the composite kidney outcome (sustained profound eGFR decline, dialysis, or transplant) by HR 0.50 (95% CI 0.32–0.77) in patients with and without baseline CKD. 1, 4
Dapagliflozin in DAPA-CKD reduced the risk of sustained eGFR decline ≥50%, end-stage kidney disease, or kidney/cardiovascular death by HR 0.61 (95% CI 0.51–0.72), with consistent benefit regardless of baseline heart failure status. 11, 12
A pooled analysis of EMPEROR trials showed empagliflozin reduced cardiovascular death or heart failure hospitalization similarly across all KDIGO risk categories, including the very-high-risk group (HR 0.84,95% CI 0.71–1.01). 5
Practical Implementation Algorithm
Step 1: Confirm Eligibility
Measure eGFR before initiation; both agents are appropriate for CKD stage 3 (eGFR 30–59) and stage 4 (eGFR 15–29). 2, 3, 6
For CKD stage 4 (eGFR 15–29), empagliflozin has slightly stronger evidence at eGFR 20–25 mL/min/1.73 m² based on EMPEROR enrollment criteria, though dapagliflozin can be continued if eGFR falls below 25 after initiation. 1, 6, 8
Step 2: Pre-Initiation Adjustments
Assess volume status and correct any depletion before starting either agent. 3, 6
Reduce loop or thiazide diuretic doses by 30–50% in patients at risk for hypovolemia (elderly, low blood pressure, or volume-depleted). 3, 6
If the patient has diabetes and is already meeting glycemic targets, lower insulin dose by approximately 20% or decrease sulfonylurea dose to prevent hypoglycemia. 3, 6
Step 3: Initiate Therapy
Prescribe either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily; do not use lower doses for heart failure or CKD indications. 1, 6, 8, 7
Do not use either agent for glucose-lowering when eGFR <45 mL/min/1.73 m² because glycemic efficacy is minimal; cardiovascular and renal benefits persist regardless. 3, 6, 7
Step 4: Monitoring Protocol
Re-measure eGFR, volume status, blood pressure, and electrolytes 2–4 weeks after initiation. 3, 6
An initial eGFR decline of 2–5 mL/min/1.73 m² within the first 2–4 weeks is expected and reflects reversible hemodynamic changes, not kidney injury; do not discontinue therapy for this reason. 3, 6
Repeat eGFR and electrolytes every 3–6 months based on CKD stage and clinical stability. 3, 6
Step 5: Continuation Strategy
Continue the same 10 mg daily dose even if eGFR falls below the initiation threshold (below 25 for dapagliflozin, below 20 for empagliflozin); stop only when dialysis or transplantation is required. 3, 6, 8, 7
Do not switch between empagliflozin and dapagliflozin unless there is a specific adverse effect or formulary requirement; they are clinically equivalent. 9, 10
Safety Considerations and Common Pitfalls
Expected Renal Effects
Do not discontinue therapy solely because of the early eGFR dip; this hemodynamic effect is not a sign of acute kidney injury and resolves within weeks. 3, 6
After the initial dip, eGFR usually stabilizes and the long-term decline slope is attenuated compared to placebo. 1, 6, 4
Genital Mycotic Infections
Genital mycotic infections occur in approximately 6–10% of users, more frequently in women and uncircumcised men. 6, 8
Provide hygiene counseling at initiation; most infections are manageable with topical antifungals without stopping the SGLT2 inhibitor. 3, 6, 8
Sick-Day Management
Educate patients to hold the SGLT2 inhibitor during acute illness with nausea, vomiting, diarrhea, or prolonged fasting to reduce the risk of euglycemic diabetic ketoacidosis. 3, 6, 8
Withhold therapy ≥3 days before major surgery and resume only after the patient is eating and drinking normally. 6, 8
Volume Depletion and Hypotension
Monitor blood pressure and volume status at follow-up visits, especially in adults ≥65 years who have higher risk of hypotension. 3, 6
Advise patients to recognize symptoms of volume depletion (dizziness, lightheadedness) and maintain adequate hydration. 6
Combination with RAS Inhibitors
Both empagliflozin and dapagliflozin reduce hyperkalemia risk without causing hypokalemia, enabling safe concurrent use with ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists. 3, 6
Do not withhold SGLT2 inhibitors when a patient is already on RAS blockade; the combination is safe and recommended. 3, 6
Contraindications and When Not to Use
Do not initiate either agent in patients already on chronic dialysis. 6, 8, 7
Do not use for glycemic control in type 1 diabetes due to increased risk of diabetic ketoacidosis. 8, 7
Do not combine dapagliflozin with empagliflozin; no additive benefit has been demonstrated. 6
Dapagliflozin is not recommended for CKD treatment in patients with polycystic kidney disease or those requiring immunosuppressive therapy for kidney disease, as it is not expected to be effective. 7